NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

@inproceedings{Amatu2016NTRKGF,
  title={NTRK gene fusions as novel targets of cancer therapy across multiple tumour types},
  author={Alessio Amatu and Andrea Sartore-Bianchi and Salvatore Siena},
  booktitle={ESMO open},
  year={2016}
}
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are expressed in human neuronal tissue and play an essential role in the physiology of development and function of the nervous system through activation by neurotrophins. Gene fusions involving NTRK genes lead to transcription of chimeric Trk… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 34 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Entrectinib ( RXDX101 ) , an oral panTrk , ROS 1 , and ALK inhibitor in patients with advanced solid 8 Amatu A , et al

S Siena, A Drillon, SH Ou
ESMO Open • 2016

Genomic profiling and efficacy of anti-EGFR therapy in appendiceal adenocarcinoma

MI Braghiroli
J Clin Oncol 2016;34(Suppl • 2016

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2015

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.

Expert opinion on investigational drugs • 2015
View 2 Excerpts

Similar Papers

Loading similar papers…